Cutera, Inc. (CUTR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cutera, Inc. (CUTR) trades at $0.10 with AI Score 46/100 (Grade C). Cutera, Inc. develops, manufactures, and markets laser and energy-based aesthetic systems. Market cap: $1.96M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CUTR: CUTR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CUTR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CUTR: the 1 perspectives are evenly split.
How is this calculated? →Cutera, Inc. (CUTR) Healthcare & Pipeline Overview
Cutera, Inc. is a medical device company specializing in laser and energy-based aesthetic systems, offering a diverse portfolio of products like Secret PRO and truSculpt for skin resurfacing and body sculpting. The company targets a global market of practitioners, including dermatologists and plastic surgeons, through a direct sales force.
What Is the Investment Thesis for CUTR?
Cutera, Inc. operates in the growing aesthetic medical device market, driven by increasing demand for non-invasive cosmetic procedures. The company's diverse product portfolio, including innovative systems like Secret PRO and truSculpt, positions it to capture market share. However, with a negative profit margin of -76.7% and a market cap of $1.96M, the company faces challenges in achieving profitability and scaling its operations. Key growth catalysts include expanding its direct sales force and launching new products. Potential risks include competition from established players and the need for regulatory approvals. Investors should closely monitor Cutera's ability to improve its financial performance and capitalize on market opportunities.
Based on FMP financials and quantitative analysis
CUTR Key Highlights
- Cutera operates in the medical device industry, specifically focusing on laser and energy-based aesthetic systems.
- The company's product portfolio includes devices for skin resurfacing, body sculpting, hair removal, and tattoo removal.
- Cutera markets and sells its products through a direct sales force to plastic surgeons, dermatologists, and other qualified practitioners.
- Cutera's gross margin is 19.5%.
- Cutera's profit margin is -76.7%.
Who Are CUTR's Competitors?
CUTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CUTR's Key Strengths?
- Diverse product portfolio of laser and energy-based aesthetic systems.
- Direct sales force targeting key practitioners.
- Established brand recognition in the aesthetic market.
- Comprehensive service and support network.
What Are CUTR's Weaknesses?
- Negative profit margin.
- High dependence on direct sales force.
- Limited geographic diversification.
- Small market capitalization.
What Could Drive CUTR Stock Higher?
- Launch of new aesthetic devices and technologies.
- Expansion of the direct sales force.
- Increasing market penetration in key geographic regions.
- Development and marketing of skincare products.
What Are the Key Risks for CUTR?
- Financial-distress signal — its Altman Z-Score of -2.78 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established players with greater resources.
- Technological obsolescence of existing products.
- Regulatory changes impacting the aesthetic market.
- Negative profit margin and financial performance.
- Economic downturns affecting consumer spending on aesthetic procedures.
What Are the Growth Opportunities for CUTR?
- Growth opportunity 1: Expanding the direct sales force to increase market penetration and drive revenue growth. A larger sales team can reach more practitioners and promote Cutera's products more effectively. The global aesthetics market is projected to reach $147.9 billion by 2028, providing a significant opportunity for Cutera to expand its sales and market share. This expansion is an ongoing effort, with potential for increased sales in the next 1-2 years.
- Growth opportunity 2: Launching new and innovative products to address unmet needs in the aesthetic market. Cutera's research and development efforts can lead to the introduction of new devices and technologies that attract new customers and drive revenue growth. The market for non-invasive aesthetic procedures is expected to grow at a CAGR of 9.8% from 2021 to 2028, indicating a strong demand for innovative solutions. New product launches are anticipated within the next 2-3 years.
- Growth opportunity 3: Increasing international expansion to tap into new markets and diversify revenue streams. Cutera can expand its presence in regions with high growth potential, such as Asia-Pacific and Latin America. The Asia-Pacific aesthetic market is projected to grow at the highest CAGR during the forecast period, driven by increasing disposable incomes and a growing awareness of aesthetic procedures. International expansion is an ongoing process, with potential for significant growth in the next 3-5 years.
- Growth opportunity 4: Enhancing customer relationships through improved service and support. Providing excellent customer service and support can increase customer loyalty and drive repeat business. The aesthetics market is highly competitive, and customer satisfaction is crucial for retaining customers and attracting new ones through referrals. Ongoing efforts to improve customer service are expected to yield positive results in the next 1-2 years.
- Growth opportunity 5: Developing and marketing skincare products to complement its aesthetic devices. Cutera can leverage its expertise in aesthetics to create and sell skincare products that enhance the results of its devices and provide an additional revenue stream. The global skincare market is projected to reach $180 billion by 2024, indicating a significant opportunity for Cutera to expand its product offerings. The development and marketing of skincare products are expected to contribute to revenue growth in the next 2-3 years.
What Opportunities Does CUTR Have?
- Expanding into new geographic markets.
- Developing and launching new products.
- Increasing sales to existing customers.
- Acquiring complementary businesses.
What Threats Does CUTR Face?
- Competition from established players.
- Technological obsolescence.
- Regulatory changes.
- Economic downturns.
What Are CUTR's Competitive Advantages?
- Proprietary technology in laser and energy-based aesthetic systems.
- Established relationships with plastic surgeons and dermatologists.
- Comprehensive service and support network.
- Brand recognition in the aesthetic market.
What Does CUTR Do?
Cutera, Inc., founded in 1988 and headquartered in Brisbane, California, is a global medical device company focused on researching, developing, manufacturing, marketing, and servicing laser and energy-based aesthetic systems. The company's evolution has been marked by continuous innovation in aesthetic technologies, catering to the growing demand for non-invasive and minimally invasive cosmetic procedures. Cutera's product portfolio includes a range of devices, such as Secret PRO, which combines fractional CO2 laser technology with radio frequency (RF) microneedling for skin resurfacing and dermal remodeling. truSculpt flex is another key product, utilizing bio-electrical muscle stimulation for body sculpting. Other notable products include excel V+ for vascular and pigmented lesion treatment, truSculpt iD for non-surgical body sculpting, and enlighten platform for tattoo removal. The company also offers the excel HR platform for hair removal and the xeo platform, a multi-application system for various aesthetic treatments. Cutera distributes skincare products and provides post-warranty services, enhancing its customer relationships. The company markets its products through a direct sales force, targeting plastic surgeons, dermatologists, and other qualified practitioners globally.
What Products and Services Does CUTR Offer?
- Researches and develops laser and energy-based aesthetic systems.
- Manufactures aesthetic devices for skin resurfacing, body sculpting, and hair removal.
- Markets its products to plastic surgeons, dermatologists, and other qualified practitioners.
- Services and supports its installed base of aesthetic systems.
- Offers post-warranty services through extended service contracts or direct billing.
- Distributes skincare products to complement its aesthetic devices.
- Provides pulsed light hand pieces for various aesthetic treatments.
- Sells hand piece refills, cycle refills, consumable tips, and marketing brochures through its website.
How Does CUTR Make Money?
- Sells laser and energy-based aesthetic systems to practitioners.
- Generates revenue from post-warranty service contracts and direct billing.
- Distributes skincare products to complement its aesthetic devices.
- Sells hand piece refills, cycle refills, and consumable tips.
What Industry Does CUTR Operate In?
Cutera operates within the medical aesthetics industry, which is experiencing growth driven by increasing demand for non-invasive and minimally invasive cosmetic procedures. The market includes established players like Cynosure, Candela, and Alma Lasers, as well as smaller, innovative companies. Cutera differentiates itself through its diverse product portfolio and focus on advanced technologies like fractional CO2 and RF microneedling. The industry is subject to regulatory oversight and requires ongoing innovation to meet evolving consumer preferences. Market trends include a growing emphasis on personalized treatments and the integration of digital technologies.
Who Are CUTR's Key Customers?
- Plastic surgeons
- Dermatologists
- Gynecologists
- Family practitioners
- Primary care physicians
How Cutera, Inc. Is Valued
Cutera, Inc. carries a market capitalization of $1.96M, placing it in the micro-cap category. Relative to its peer group, CUTR's quantitative score of 46/100 is below the peer average of 69/100.
ROE 174%Key Financial Metrics
Return on equity for Cutera, Inc. stands at 174.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.0%, showing how much profit it generates from its asset base. A current ratio of 3.07 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Cutera, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.78 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Cutera, Inc. revenue of about $161.3M for fiscal 2026, with EPS near $-1.94.
CUTR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Cutera's future performance, indicating that executives believe the company is undervalued.
- Community sentiment has shifted positively, with discussions highlighting innovative product launches that could drive future growth.
- Analysts are noting improvements in operational efficiency, which may enhance profitability and attract more investors.
- Market perception is optimistic as Cutera expands its presence in the aesthetic device sector, tapping into a growing consumer demand.
Bear Case
- Concerns around regulatory scrutiny in the medical device industry have surfaced, leading to apprehension among some investors.
- Social sentiment shows a segment of the community worried about competition from larger players, which may impact market share.
- Recent earnings reports have raised questions about revenue sustainability, prompting skepticism about long-term growth projections.
- Negative commentary on social platforms hints at a lack of confidence in management's ability to navigate market challenges effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CUTR Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Jun 8, 2021
CUTR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CUTR.
Price Targets
Wall Street price target analysis for CUTR.
CUTR MoonshotScore
What does this score mean?
The MoonshotScore rates CUTR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Taylor C. Harris
CEO
Taylor C. Harris serves as the Chief Executive Officer of Cutera, Inc. His professional background includes extensive experience in the medical device industry, with a focus on strategic leadership and operational excellence. Prior to joining Cutera, Harris held various leadership positions at other medical technology companies, contributing to their growth and market expansion. His expertise lies in driving innovation, optimizing business processes, and building high-performing teams. Harris is responsible for overseeing all aspects of Cutera's operations and guiding the company's strategic direction.
Track Record: Since assuming the role of CEO, Taylor C. Harris has focused on enhancing Cutera's product portfolio and expanding its market reach. Key initiatives under his leadership include the launch of new products and the implementation of strategies to improve the company's financial performance. He has also emphasized the importance of customer satisfaction and has worked to strengthen Cutera's relationships with its customers. His leadership aims to drive sustainable growth and create long-term value for shareholders.
CUTR Healthcare Stock FAQ
What does Cutera, Inc. do?
Cutera, Inc. is a medical device company that researches, develops, manufactures, markets, and services laser and energy-based aesthetic systems. Their product portfolio includes devices for skin resurfacing (like Secret PRO), body sculpting (truSculpt flex and truSculpt iD), hair removal (excel HR), and tattoo removal (enlighten platform). They sell these systems to practitioners such as plastic surgeons and dermatologists through a direct sales force, along with providing ongoing service, support, and consumable products.
What do analysts say about CUTR stock?
Due to the provided data not containing analyst ratings or price targets, a summary of analyst consensus for Cutera, Inc. (CUTR) cannot be provided. Investors should consult independent financial research platforms for the latest analyst ratings, price targets, and financial analysis to inform their investment decisions. These resources typically provide insights into valuation metrics, growth considerations, and potential risks associated with the stock.
What are the main risks for CUTR?
Cutera, Inc. faces several risks inherent in the medical device industry and its specific business model. Intense competition from larger, more established players with greater financial resources poses a significant threat. Rapid technological advancements could render existing products obsolete, requiring continuous innovation and investment in research and development. Regulatory changes in the aesthetic market could impact the company's ability to market and sell its products. The company's current negative profit margin and overall financial performance present ongoing challenges. Economic downturns could reduce consumer spending on elective aesthetic procedures, impacting revenue.
What are the key factors to evaluate for CUTR?
Cutera, Inc. (CUTR) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CUTR data refresh on this page?
CUTR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CUTR's recent stock price performance?
Cutera, Inc. (CUTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio of laser and energy-based aesthetic systems. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CUTR overvalued or undervalued right now?
Valuing Cutera, Inc. (CUTR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CUTR?
Before investing in Cutera, Inc. (CUTR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the provided information and may not be current.
- Analyst ratings and price targets are not available in the provided data.